1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Lactate Dehydrogenase

Lactate Dehydrogenase

Lactate Dehydrogenase (LDH), which catalyzes the inter-conversion of pyruvate and lactate.

Mammalian lactate dehydrogenase (LDH) comprises three major families of conserved enzymes that catalyse the reversible interconversion of pyruvate and lactate, a key metabolic step in glycolysis and other metabolic pathways. At least five LDH tetrameric isozymes are reported in somatic mammalian tissues, comprising LDHA and LDHB subunits, whereas LDHC4 is found only in mature testis and spermatozoa, where it is required for male fertility. Lactate dehydrogenase catalyzes the interconversion of pyruvate and lactate with concomitant interconversion of NADH and NAD+. At high concentrations of lactate, the enzyme exhibits feedback inhibition, and the rate of conversion of pyruvate to lactate is decreased. Dihydroorotate dehydrogenase (DHODH) is a key enzyme that catalyzes the oxidation of dihydroorotate (DHO) to produce orotate, a key step in pyrimidine biosynthesis.

Lactate Dehydrogenase Related Products (25):

Cat. No. Product Name Effect Purity
  • HY-100681
    GSK2837808A Inhibitor >99.0%
    GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 1.9 and 14 nM for LDHA and LDHB, respectively.
  • HY-100742A
    (R)-GNE-140 Inhibitor 98.50%
    (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC50s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.
  • HY-112645
    BAY-2402234 Inhibitor 98.12%
    BAY-2402234 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies.
  • HY-100742
    GNE-140 racemate Inhibitor 99.53%
    GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. (R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor.
  • HY-16214
    FX-11 Inhibitor 98.11%
    FX-11 (LDHA Inhibitor FX11) is a potent lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 23.3 μM for HeLa cell,a Ki value of 8 μM.
  • HY-128787
    DHODH-IN-5 Inhibitor
    DHODH-IN-5 is a human dihydroorotate dehydrogenase (DHODH) in hibitor, with a pIC50 of 7.8 for human recombinant DHODH. DHODH-IN-5 inhibits measles virus replication, with a pMIC50 of 8.8.
  • HY-135666
    DHODH-IN-8 Inhibitor
    DHODH-IN-8 (Compound 27) is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase with IC50s of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively. DHODH-IN-8 has antimalarial activity.
  • HY-135664
    DHODH-IN-7 Inhibitor
    DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC50 of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia.
  • HY-14908
    Vidofludimus Inhibitor 99.14%
    Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.
  • HY-111108
    LDH-IN-1 Inhibitor 99.84%
    LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC50s of 32 and 27 nM for LDHA and LDHB, respectively.
  • HY-124593
    PTC299 Inhibitor 99.39%
    PTC299 is a potent, orally bioavailable VEGFA inhibitor, targets dihydroorotate dehydrogenase (DHODH), resulting in cell growth inhibition and differentiation in leukemias, including acute myeloid leukemia, linking DHODH regulation and stress-induced VEGFA and angiogenesis.
  • HY-100742B
    (S)-GNE-140 Inhibitor
    (S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).
  • HY-W040073
    Nifurtimox Inhibitor 99.64%
    Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
  • HY-120924
    BRD9185 Inhibitor
    BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC50 of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model.
  • HY-135676
    DHODH-IN-12 Inhibitor
    DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.
  • HY-135678
    DHODH-IN-14 Inhibitor
    DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.49 μM for rat liver DHODH. DHODH-IN-14 can be used to treat rheumatoid arthritis.
  • HY-135677
    DHODH-IN-13 Inhibitor
    DHODH-IN-13 (Compound 7a) is a hydroxyfurazan analog of A771726. DHODH-IN-13 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 4.3 μM for rat liver DHODH. DHODH-IN-13 can be used to treat rheumatoid arthritis.
  • HY-135658
    hDHODH-IN-1 Inhibitor
    hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor. hDHODH-IN-1 has anti-inflammatory effect.
  • HY-135648
    PfDHODH-IN-1 Inhibitor
    PfDHODH-IN-1 is an analogue of the active metabolite of Leflunomide. PfDHODH-IN-1 is a Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor. PfDHODH-IN-1 has antimalarial activity.
  • HY-135675
    DHODH-IN-11 Inhibitor
    DHODH-IN-13 (Compound 7a) is a hydroxyfurazan analog of A771726. DHODH-IN-13 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 4.3 μM for rat liver DHODH. DHODH-IN-13 can be used to treat rheumatoid arthritis.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.